Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanctura Co-Promotion Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Esprit Pharma has become Indevus' new co-promotion partner for Sanctura (trospium), after acquiring marketing rights for the overactive bladder agent from Pliva

You may also be interested in...



Indevus Sanctura XR To Begin Phase III Trials “Shortly”

Firm targets second half of 2006 for NDA submission for the extended-release formulation of the overactive bladder treatment. Sanctura maintains 3% share of new prescriptions in the quarter despite heavy promotion from competitors.

Indevus Sanctura XR To Begin Phase III Trials “Shortly”

Firm targets second half of 2006 for NDA submission for the extended-release formulation of the overactive bladder treatment. Sanctura maintains 3% share of new prescriptions in the quarter despite heavy promotion from competitors.

Indevus To Market Nebido In The U.S. Upon Approval

Indevus expects to file an NDA for the injectable testosterone therapy, licensed from Schering AG, for the treatment of hypogonadism in the second half of 2006.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel